JP6553615B2 - 疼痛に対して多重モードの活性を有するピペラジン誘導体 - Google Patents
疼痛に対して多重モードの活性を有するピペラジン誘導体 Download PDFInfo
- Publication number
- JP6553615B2 JP6553615B2 JP2016539896A JP2016539896A JP6553615B2 JP 6553615 B2 JP6553615 B2 JP 6553615B2 JP 2016539896 A JP2016539896 A JP 2016539896A JP 2016539896 A JP2016539896 A JP 2016539896A JP 6553615 B2 JP6553615 B2 JP 6553615B2
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- substituted
- phenyl
- triazol
- unsubstituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 C*Cc1n[n]cn1 Chemical compound C*Cc1n[n]cn1 0.000 description 7
- TZEGGLAQRXWSCY-UHFFFAOYSA-N CN(C1)CC2C1CN(C)C2 Chemical compound CN(C1)CC2C1CN(C)C2 TZEGGLAQRXWSCY-UHFFFAOYSA-N 0.000 description 2
- HWTLFOPXWFNIAJ-UHFFFAOYSA-N CN1C2CN(C)CC1CC2 Chemical compound CN1C2CN(C)CC1CC2 HWTLFOPXWFNIAJ-UHFFFAOYSA-N 0.000 description 2
- HWTLFOPXWFNIAJ-JAMMHHFISA-N CN1C2CN(C)C[C@@H]1CC2 Chemical compound CN1C2CN(C)C[C@@H]1CC2 HWTLFOPXWFNIAJ-JAMMHHFISA-N 0.000 description 1
- YQWYNMOCRRYVCE-UHFFFAOYSA-N CN1CCN(C)CCC1 Chemical compound CN1CCN(C)CCC1 YQWYNMOCRRYVCE-UHFFFAOYSA-N 0.000 description 1
- SZQCPPRPWDXLMM-UHFFFAOYSA-N Cc1c[n](C)nc1 Chemical compound Cc1c[n](C)nc1 SZQCPPRPWDXLMM-UHFFFAOYSA-N 0.000 description 1
- OJAWOLWHEQUTDE-UHFFFAOYSA-N Cc1c[n](C)nn1 Chemical compound Cc1c[n](C)nn1 OJAWOLWHEQUTDE-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
- C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D249/14—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13384006.6 | 2013-12-20 | ||
| EP13384006 | 2013-12-20 | ||
| PCT/EP2014/078852 WO2015092009A1 (en) | 2013-12-20 | 2014-12-19 | Piperazine derivatives having multimodal activity against pain |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016540792A JP2016540792A (ja) | 2016-12-28 |
| JP2016540792A5 JP2016540792A5 (enExample) | 2018-02-01 |
| JP6553615B2 true JP6553615B2 (ja) | 2019-07-31 |
Family
ID=49998042
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016539896A Expired - Fee Related JP6553615B2 (ja) | 2013-12-20 | 2014-12-19 | 疼痛に対して多重モードの活性を有するピペラジン誘導体 |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US10351535B2 (enExample) |
| EP (1) | EP3083563A1 (enExample) |
| JP (1) | JP6553615B2 (enExample) |
| KR (1) | KR20160098506A (enExample) |
| CN (1) | CN105829287B (enExample) |
| AU (1) | AU2014368368C1 (enExample) |
| CA (1) | CA2932051A1 (enExample) |
| IL (1) | IL245808B (enExample) |
| MA (1) | MA39145B1 (enExample) |
| MX (1) | MX2016008130A (enExample) |
| MY (1) | MY179509A (enExample) |
| PH (1) | PH12016500978A1 (enExample) |
| RU (1) | RU2709482C1 (enExample) |
| SG (1) | SG10201805267UA (enExample) |
| TN (1) | TN2016000203A1 (enExample) |
| UA (1) | UA120754C2 (enExample) |
| WO (1) | WO2015092009A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2018521090A (ja) * | 2015-07-29 | 2018-08-02 | ラボラトリオス・デル・デエレ・エステベ・エセ・ア | 疼痛に対する多様な活性を有するアミド誘導体 |
| AR105522A1 (es) * | 2015-07-29 | 2017-10-11 | Esteve Labor Dr | Derivados de amida sustituida que tienen actividad multimodal contra el dolor |
| JP2019516736A (ja) * | 2016-05-20 | 2019-06-20 | エステベ ファーマシューティカルズ，エセ．アー． | 疼痛に対する多様な活性を有するテトラヒドロピラン誘導体およびチオピラン誘導体 |
| US10961249B2 (en) * | 2017-03-21 | 2021-03-30 | Temple University-Of The Commonwealth System Of Higher Education | Modulators of the sigma-2 receptor and their method of use |
| JP7365238B2 (ja) * | 2017-03-21 | 2023-10-19 | テンプル・ユニバーシティ－オブ・ザ・コモンウェルス・システム・オブ・ハイアー・エデュケイション | ５－ヒドロキシトリプタミン受容体７調節物質および治療剤としてのその使用 |
| MD3762368T2 (ro) | 2018-03-08 | 2022-07-31 | Incyte Corp | Compuși diol aminopirazină ca inhibitori ai PI3K-Y |
| US11046658B2 (en) | 2018-07-02 | 2021-06-29 | Incyte Corporation | Aminopyrazine derivatives as PI3K-γ inhibitors |
| TWI824050B (zh) * | 2018-10-31 | 2023-12-01 | 西班牙塔拉森斯調理協會 | 化合物、製備化合物的方法、化合物的用途、藥物組合物、用作藥物的化合物及用作治療疼痛的藥物的化合物 |
| EP3753932A1 (en) * | 2019-06-17 | 2020-12-23 | Esteve Pharmaceuticals, S.A. | Substituted bicyclic derivatives having multimodal activity against pain |
| WO2022187206A1 (en) * | 2021-03-01 | 2022-09-09 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Dual-target mu opioid and dopamine d3 receptors ligands; preparation and use thereof |
| WO2024105225A1 (en) | 2022-11-18 | 2024-05-23 | Universitat De Barcelona | Synergistic combinations of a sigma receptor 1 (s1r) antagonist and a soluble epoxide hydrolase inhibitor (sehi) and their use in the treatment of pain |
| CN117800942B (zh) * | 2023-12-13 | 2025-04-25 | 徐州医科大学 | 一种噻吩哌嗪酰胺类衍生物、组合物及其应用 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2580648B1 (fr) * | 1985-04-17 | 1987-05-15 | Adir | Nouveaux derives du triazole, leur procede de preparation et les compositions pharmaceutiques les renfermant |
| DK93087A (da) * | 1986-02-27 | 1987-08-28 | Duphar Int Res | Hidtil ukendte aryl substituerede (n-piperidinyl)methyl- og (n-piperazinyl)methylazoler med antipsykotiske egenskaber |
| SE0103818D0 (sv) | 2001-11-15 | 2001-11-15 | Astrazeneca Ab | Chemical compounds |
| US7262194B2 (en) | 2002-07-26 | 2007-08-28 | Euro-Celtique S.A. | Therapeutic agents useful for treating pain |
| WO2007123269A1 (ja) * | 2006-04-19 | 2007-11-01 | Astellas Pharma Inc. | アゾールカルボキサミド誘導体 |
| WO2008008480A2 (en) | 2006-07-12 | 2008-01-17 | Cumbre Pharmaceuticals Inc. | Nitroheteroaryl-containing rifamycin derivatives |
| KR20090029274A (ko) * | 2006-07-21 | 2009-03-20 | 아이알엠 엘엘씨 | Ｉｔｐｋｂ 억제제로서의 화합물 및 조성물 |
| MX2009004786A (es) * | 2006-10-31 | 2009-06-05 | Schering Corp | Derivados de anilinopiperazina y sus metodos de uso. |
| CA2673918C (en) * | 2006-12-27 | 2015-02-17 | Sanofi-Aventis | Substituted isoquinoline and isoquinolinone derivatives |
| RU2498982C2 (ru) * | 2007-04-16 | 2013-11-20 | Грюненталь Гмбх | Новые лиганды ванилоидных рецепторов и их применение для изготовления лекарственных средств |
| EP1982714A1 (en) * | 2007-04-16 | 2008-10-22 | Laboratorios del Dr. Esteve S.A. | Pyrano-pyrazole-amines |
| DK2155717T3 (da) * | 2007-05-11 | 2012-11-19 | Lilly Co Eli | 2-[4-(pyrazol-4-ylalkyl)piperazin-1-yl]-3-phenyl-pyraziner og -pyridiner og 3-[4-(pyrazol-4-ylalkyl)piperazin-1-yl]-2-phenyl-pyridiner som 5-ht7-receptorantagonister |
| US7842696B2 (en) | 2007-06-21 | 2010-11-30 | Forest Laboratories Holdings Limited | Piperazine derivatives as inhibitors of stearoyl-CoA desaturase |
| TW200914020A (en) * | 2007-08-28 | 2009-04-01 | Lilly Co Eli | Substituted piperazinyl pyrazines and pyridines as 5-HT7 receptor antagonists |
| KR20140139125A (ko) | 2007-08-31 | 2014-12-04 | 퍼듀 퍼머 엘피 | 치환-퀴녹살린-형 피페리딘 화합물 및 그의 용도 |
| WO2010046780A2 (en) | 2008-10-22 | 2010-04-29 | Institut Pasteur Korea | Anti viral compounds |
| CN102271681B (zh) * | 2008-11-04 | 2014-11-12 | 凯莫森特里克斯股份有限公司 | Cxcr7调节剂 |
| US8853202B2 (en) * | 2008-11-04 | 2014-10-07 | Chemocentryx, Inc. | Modulators of CXCR7 |
| EP2375899B1 (en) | 2009-01-12 | 2015-02-25 | Array Biopharma Inc. | Piperidine-containing compounds and use thereof in the treatment of diabetes |
| MX340870B (es) | 2010-02-12 | 2016-07-27 | Pharmascience Inc | Compuestos de unión del dominio de repetición de inhibidores de proteínas de apoptosis de baculovirus. |
| EP2395003A1 (en) * | 2010-05-27 | 2011-12-14 | Laboratorios Del. Dr. Esteve, S.A. | Pyrazole compounds as sigma receptor inhibitors |
| EP2576520A1 (en) | 2010-05-28 | 2013-04-10 | GE Healthcare UK Limited | Radiolabeled compounds and methods thereof |
-
2014
- 2014-12-19 CN CN201480069503.2A patent/CN105829287B/zh not_active Expired - Fee Related
- 2014-12-19 MA MA39145A patent/MA39145B1/fr unknown
- 2014-12-19 TN TN2016000203A patent/TN2016000203A1/en unknown
- 2014-12-19 EP EP14815384.4A patent/EP3083563A1/en not_active Withdrawn
- 2014-12-19 US US15/106,423 patent/US10351535B2/en not_active Expired - Fee Related
- 2014-12-19 MX MX2016008130A patent/MX2016008130A/es unknown
- 2014-12-19 KR KR1020167019809A patent/KR20160098506A/ko not_active Ceased
- 2014-12-19 SG SG10201805267UA patent/SG10201805267UA/en unknown
- 2014-12-19 UA UAA201607879A patent/UA120754C2/uk unknown
- 2014-12-19 AU AU2014368368A patent/AU2014368368C1/en not_active Ceased
- 2014-12-19 JP JP2016539896A patent/JP6553615B2/ja not_active Expired - Fee Related
- 2014-12-19 WO PCT/EP2014/078852 patent/WO2015092009A1/en not_active Ceased
- 2014-12-19 MY MYPI2016701867A patent/MY179509A/en unknown
- 2014-12-19 CA CA2932051A patent/CA2932051A1/en not_active Abandoned
- 2014-12-19 RU RU2016129110A patent/RU2709482C1/ru not_active IP Right Cessation
-
2016
- 2016-05-24 IL IL245808A patent/IL245808B/en active IP Right Grant
- 2016-05-25 PH PH12016500978A patent/PH12016500978A1/en unknown
-
2019
- 2019-05-30 US US16/426,024 patent/US10745361B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US10351535B2 (en) | 2019-07-16 |
| JP2016540792A (ja) | 2016-12-28 |
| TN2016000203A1 (en) | 2017-10-06 |
| MX2016008130A (es) | 2016-10-13 |
| WO2015092009A1 (en) | 2015-06-25 |
| US10745361B2 (en) | 2020-08-18 |
| MY179509A (en) | 2020-11-09 |
| KR20160098506A (ko) | 2016-08-18 |
| PH12016500978A1 (en) | 2016-06-20 |
| US20190276415A1 (en) | 2019-09-12 |
| IL245808B (en) | 2020-03-31 |
| SG10201805267UA (en) | 2018-07-30 |
| AU2014368368B2 (en) | 2019-01-31 |
| RU2709482C1 (ru) | 2019-12-18 |
| MA39145B1 (fr) | 2018-05-31 |
| AU2014368368A1 (en) | 2016-07-07 |
| US20170001967A1 (en) | 2017-01-05 |
| CN105829287B (zh) | 2019-08-27 |
| CN105829287A (zh) | 2016-08-03 |
| IL245808A0 (en) | 2016-08-02 |
| AU2014368368C1 (en) | 2019-06-27 |
| RU2016129110A (ru) | 2018-01-23 |
| CA2932051A1 (en) | 2015-06-25 |
| UA120754C2 (uk) | 2020-02-10 |
| EP3083563A1 (en) | 2016-10-26 |
| MA39145A1 (fr) | 2017-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016540792A (ja) | 疼痛に対して多重モードの活性を有するピペラジン誘導体 | |
| EP3083601B1 (en) | Piperidine derivatives having multimodal activity against pain | |
| JP6535687B2 (ja) | 疼痛に対する多様な活性を有する１−オキサ−４，９−ジアザスピロウンデカン化合物のアルキルおよびアリール誘導体 | |
| JP6516773B2 (ja) | 疼痛に対する多様な活性を有する１−オキサ−４，９−ジアザスピロウンデカン化合物のアミド誘導体 | |
| JP2018525363A (ja) | 疼痛に対する多様な活性を有する置換アミド誘導体 | |
| CN106488921A (zh) | 醛固酮合成酶抑制剂 | |
| JP6498672B2 (ja) | 疼痛に対して多重モードの活性を有するピペリジン化合物 | |
| JP2013521250A (ja) | アミノインダンの誘導体、これらの調製および治療におけるこれらの適用 | |
| TW202144359A (zh) | 針對疼痛具有多模態活性之吡唑并〔１，５－ａ〕嘧啶衍生物 | |
| JP2017535566A (ja) | 疼痛に対する多様な活性を有する１，９−ジアザスピロウンデカン化合物 | |
| JP2018533598A (ja) | 薬物乱用の治療および薬物中毒の治療のためのオキサ−アザスピロ化合物 | |
| JP7654648B2 (ja) | 疼痛に対する多様な活性を有するホモピペラジニル及びホモピペリジニルキナゾリン－４（３ｈ）－オン誘導体 | |
| JP2019516736A (ja) | 疼痛に対する多様な活性を有するテトラヒドロピラン誘導体およびチオピラン誘導体 | |
| JP6844822B2 (ja) | 疼痛に対して活性を有する置換モルホリン誘導体 | |
| JP2025529974A (ja) | 置換テトラヒドロシクロヘプタ［ｅ］インドール誘導体、それらの調製のプロセス及びその治療的使用 | |
| TWI680121B (zh) | 具有抗疼痛之多重模式活性的哌𠯤衍生物 | |
| JP2018521090A (ja) | 疼痛に対する多様な活性を有するアミド誘導体 | |
| TW201627301A (zh) | 具有抗疼痛之多重模式活性的哌啶化合物 | |
| JP2025512050A (ja) | 新規の置換された４－アミノ－４－オキソ－ブト－２－エニル誘導体、それらの調製のためのプロセス及びその治療的使用 | |
| HK40085749A (en) | P2x3 modulators | |
| TW201627300A (zh) | 具有抗疼痛之多重模式活性的哌啶衍生物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20171215 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20171215 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20180906 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180925 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20181210 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20190122 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190408 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20190625 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20190704 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6553615 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| LAPS | Cancellation because of no payment of annual fees |